Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter
YouTube

13°
- Broken Bow, NE (68822)
  Today
  
  Periods of snow and windy. High 19F. Winds NNW at 20 to 30 mph. Chance of snow 100%. 5 to 8 inches of snow expected. Higher wind gusts possible..
  
  Tonight
  
  Snow showers this evening. Becoming partly cloudy later. Low 3F. Winds NW at 10 to 20 mph. Chance of snow 50%.
  
  Updated: February 19, 2026 @ 7:59 am
- Full Forecast

Site search

Home
News
- Local News
Sports
Obituaries
Photos
Videos
e-Edition
Classifieds
- Legal Notices
Business Directory

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

28.23 -0.93 (-3.19%)

Streaming Delayed Price Updated: 9:59 AM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Despite its growth, NASDAQ:GMAB remains within the realm of affordability. ↗

June 21, 2024

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

10 Analysts Assess Genmab: What You Need To Know ↗

June 20, 2024

Via Benzinga

7 Stocks That Could Safely 10X by 2030 ↗

June 06, 2024

Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align.

Via InvestorPlace

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

June 03, 2024

From Genmab A/S

Via Business Wire

What 9 Analyst Ratings Have To Say About Genmab ↗

May 20, 2024

Via Benzinga

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

May 02, 2024

Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).

Via Chartmill

Decoding 9 Analyst Evaluations For Genmab ↗

April 30, 2024

Via Benzinga

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

June 02, 2024

From Genmab A/S

Via Business Wire

Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 24, 2024

Via Benzinga

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024

From Genmab A/S

Via Business Wire

NASDAQ:GMAB is not too expensive for the growth it is showing. ↗

April 11, 2024

Via Chartmill

Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? ↗

March 28, 2024

Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.

Via Chartmill

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

June 01, 2024

From Genmab A/S

Via Business Wire

Genmab Completes Acquisition of ProfoundBio

May 21, 2024

From Genmab A/S

Via Business Wire

Analyst Ratings For Genmab ↗

March 26, 2024

Via Benzinga

4 Analysts Assess Genmab: What You Need To Know ↗

February 20, 2024

Via Benzinga

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗

May 20, 2024

Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.

Via InvestorPlace

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

May 14, 2024

From Genmab A/S

Via Business Wire

GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

April 29, 2024

From Genmab A/S

Via Business Wire

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

April 29, 2024

From Pfizer Inc.

Via Business Wire

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗

April 25, 2024

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

Via Investor's Business Daily

ProfoundBio Discovers The Joys Of Having A Wealthy Owner ↗

April 08, 2024

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...

Via Benzinga

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio ↗

April 03, 2024

Genmab is buying a privately held company focused on antibody drug conjugates.

Via Investor's Business Daily

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

April 03, 2024

From Genmab A/S

Via Business Wire

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

March 21, 2024

For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering.

Via Chartmill

Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

March 05, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

February 29, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

February 27, 2024

From Genmab A/S

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Business
Entertainment
Local Events
Obituaries
Multimedia
Online Features

Services

Subscription Services
Pay Your Bill
Classifieds
Promote Your Event
Email Alerts
Place an Ad
Rack Locations
Search
Weather

custercountychief.com
311 South 10th Avenue
Broken Bow, NE 68822
Phone: 308-872-2471
Email: publisher@custercountychief.com

Facebook
Twitter
YouTube

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Broken Bow, NE (68822)

Today

Tonight

Genmab A/S - American Depositary Shares (NQ:GMAB)

All News about Genmab A/S - American Depositary Shares

Sections

Services

Follow Us